Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|10 CitationsLongevity & Cellular

FOXO4-DRI Dosing Protocol: Senolytic Peptide Guide

Also known as: FOXO4-p53 Senolytic Peptide, D-Retro-Inverso FOXO4

Dose Range
5–10 mgResearch range
0Typical research window: 5–10 mg12.5 mg

Studied in published research — not a medical recommendation. Primary protocol (Senolytic Protocol): 5-10 mg, Daily.

Protocol at a Glance
How Often
Daily

Daily

A Typical Run
8-16 weeks

Mouse studies show lifespan extension and frailty reduction

How It's Taken
Vial

Subcutaneous injection

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

20 mg vial · 2 mL water · 0.5 mL syringe
Concentration: 10 mg in every mL (100 mcg per unit)
0u10u20u30u40u50u
Low end: 5 mg50 units
High end: 10 mg100 units

All U-100: 100 units = 1 mL. 4 doses in the vial at the low end (2 doses at the high end).

Track the doses you run

Save FOXO4-DRI (Proxofim) to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

Research / Non-FDATier 3 — Translational Animal & Clinical Obs
Pharmacological Class
Targeted Senolytic p53-FOXO4 Disruptor Peptide
Administration Route
Under-the-skin injection (Subcutaneous injection)
2026 FDA & 503A Status
Unapproved investigational compound in the US; not listed on the FDA 503A Bulk Drug Substances positive list. Available for laboratory research with third-party HPLC + LC-MS COA verification.
WADA Sport Status
Prohibited at All Times (WADA S0 Unapproved Substances & S2.2 Peptide Hormones, Growth Factors & Mimetics)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. FOXO4-DRI (Proxofim) is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

FOXO4-DRI is a senolytic peptide designed to selectively eliminate senescent cells. It disrupts the interaction between FOXO4 and p53, allowing p53 to trigger apoptosis in aged, damaged cells.

Mechanisms of Action

  • Blocks FOXO4-p53 interaction in senescent cells
  • Releases p53 to nucleus triggering apoptosis
  • Selectively targets senescent cells sparing healthy tissue
  • Reduces senescence-associated secretory phenotype (SASP)

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Senolytic Protocol
animal study
5-10 mgDaily8-16 weeksSubcutaneous injectionanimal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Systemic Inflammation, Tissue Repair & Immune Biomarker Panel (FOXO4-DRI (Proxofim))

Objective inflammatory, hematologic, and trace-mineral markers to quantify connective-tissue recovery, cytokine resolution, and organ safety.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

hs-CRP (High-Sensitivity C-Reactive Protein)

Day 0 + Wk 6–8

Why track at baseline: Quantifies baseline systemic IL-6/NF-κB inflammatory burden from tendon, joint, gut, or vascular injury.

Week 6–8 check: Target <1.0 mg/L (optimal <0.5 mg/L) by Week 6–8 as tissue inflammation resolves.

ESR (Sedimentation Rate) & Ferritin

Day 0 + Wk 6–8

Why track at baseline: Tracks chronic connective-tissue and autoimmune/mucosal inflammatory activity alongside iron stores.

Week 6–8 check: Downward trend in ESR confirming structural resolution rather than temporary analgesic masking.

CBC with Differential (WBC, Neutrophil/Lymphocyte Ratio)

Day 0 + Wk 6–8

Why track at baseline: Evaluates innate/adaptive immune balance (especially for Thymosin Alpha-1, Thymosin Beta-4, LL-37 & KPV).

Week 6–8 check: Balanced lymphocyte count and improved Neutrophil-to-Lymphocyte Ratio (NLR 1.2–2.0).

CMP (Liver/Kidney) + Serum Copper & Zinc Ratio

Day 0 + Wk 6–8

Why track at baseline: Verifies baseline hepatic/renal function and checks Copper:Zinc balance before GHK-Cu / GLOW / KLOW protocols.

Week 6–8 check: Maintain 1:1 to 1.2:1 Zinc-to-Copper equilibrium and normal transaminases/creatinine.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

3 Human6 Animal1 In Vitro

Injection of FOXO4-DRI in both naturally aged and induced aging mice effectively suppressed aortic aging and improved aortic function. Additionally, we found that FOXO4-DRI alleviates endothelial cell senescence induced by OGD, thereby enhancing endothelial cell function.

Limitations: Animal study only — human translation uncertain.

2026|Frontiers in bioengineering and biotechnology
PubMed

Furthermore, we show that p53 phosphorylation enhances the affinity for both FOXO4 and FOXO4-DRI. Summarizing we provide a detailed characterization of the interaction of p53 with FOXO4 and FOXO4-DRI which is the basis for development of p53 inhibitors to treat diseases linked to cellular senescence such as cancers.

Limitations: No placebo control reported.

2025|Nature communications
PubMed

Our study indicates that upregulation of p53-pS15 and p16 maintains a persistent senescent microenvironment to promote cell cycle arrest and apoptosis resistance in keloid fibroblasts. FOXO4-DRI shows potential as a treatment targeting the senescence and apoptosis resistance, and holds promise as an approach to prevent the aggressiveness and relapse of keloids.

Limitations: No placebo control reported.

2025|Communications biology
PubMed

In this study, we observed that FOXO4-DRI, a specific FOXO4- p53 binding blocker, induced apoptosis in senescent Leydig cells, reduced the secretion of certain Senescence-Associated Secretory Phenotype and improved the proliferation of cocultured GC-1 SPG cells. In naturally aged mice, FOXO4-DRI-treated aged mice exhibited increased sperm quality and improved spermatogenesis.

Limitations: Animal study only — human translation uncertain.

2024|Experimental gerontology
PubMed

Patients with pulmonary arterial hypertension compared with controls exhibited high lung p16, p21, and &#x3b3;-H2AX protein levels, with abundant vascular cells costained for p16, &#x3b3;-H2AX, and 53BP1. Hypoxia increased thoracic bioluminescence in p16LUC/+ mice.

Limitations: Animal study only — human translation uncertain.

2023|Circulation
PubMed

We also found the FOXO4-DRI resets the distribution of intranuclear p53 and concurrently decreased the total ECM proteins content. After further validation, FOXO4-DRI may well be a promising therapeutic approach to treating pulmonary fibrosis.

Limitations: Animal study only — human translation uncertain.

2023|Naunyn-Schmiedeberg's archives of pharmacology
PubMed

In addition, in this study, we also uncovered an obvious therapeutic effect of FOXO4-DRI on alleviating radiation-induced pulmonary fibrosis (RIPF) by targeting senescence-like fibroblasts in vivo. In conclusion, by targeting senescence, we offer a strategy that simultaneously decreases radioresistance of NSCLC and the incidence of RIPF.

Limitations: No placebo control reported.

2022|JCI insight
PubMed

However, the cartilage tissue generated from FOXO4-DRI pretreated PDL9 cells displayed lower expression of senescence-relevant secretory factors than that from the untreated control group. Taken together, FOXO4-DRI is able to remove the senescent cells in PDL9 chondrocytes, but its utility in promoting cartilage formation from the in vitro expanded chondrocytes needs further investigation.

Limitations: In-vitro study — may not reflect in-vivo effects.

2022|Frontiers in bioengineering and biotechnology
PubMed

The inhibited effect of FOXO4-DRI on myofibroblast lead to a downregulation of extracellular matrix (ECM) receptor interaction pathway in BLM-induced PF. Above all, FOXO4-DRI ameliorates BLM-induced PF in mouse and may be served as a viable therapeutic option for PF.

Limitations: Animal study only — human translation uncertain.

2022|Journal of cellular and molecular medicine
PubMed

In naturally aged mice, FOXO4-DRI improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency. These findings reveal the therapeutic potential of FOXO4-DRI for the treatment of male late-onset hypogonadism.

Limitations: Animal study only — human translation uncertain.

2021|Aging
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •No human safety data available
  • •Potential for excessive cell death if overdosed
  • •Not FDA approved; highly experimental
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get FOXO4-DRI (Proxofim), baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Trusted Voices

X/Twitter accounts discussing this peptide

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.